Young-Suk Lim
University of Ulsan
H-index: 75
Asia-South Korea
Top articles of Young-Suk Lim
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks | Alimentary Pharmacology & Therapeutics | Scott K Fung Calvin Q Pan Grace Lai‐Hung Wong Wai‐Kay Seto Sang Hoon Ahn | 2024/1 |
Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-Positive patients | Hepatology | Won-Mook Choi Terry Cheuk-Fung Yip W Ray Kim Leland J Yee Craig Brooks-Rooney | 2024/1/24 |
Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model | Liver International | Jonggi Choi Jina Park Won‐Mook Choi Danbi Lee Ju Hyun Shim | 2024/2/20 |
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection | JHEP Reports | Harry L Janssen Young-Suk Lim Hyung Joon Kim Leonard Sowah Cheng-Hao Tseng | 2024/2/1 |
Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B | Gut | Won-Mook Choi Gi-Ae Kim Jonggi Choi Gwang Hyeon Choi Yun Bin Lee | 2024/4/1 |
Gray zone of hepatitis B virus infection | Young-Suk Lim | 2024/3/1 | |
Introducing W. Ray Kim, MD, Our 2024 AASLD president | Hepatology | Young-Suk Lim Allison J Kwong Alina M Allen | 2024/1/1 |
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide | Clinical and Molecular Hepatology | Hyeyeon Hong Won-Mook Choi Danbi Lee Ju Hyun Shim Kang Mo Kim | 2024/1 |
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories | Journal of Hepatology | Devin Razavi-Shearer H Child K Razavi-Shearer A Voeller H Razavi | 2024/2/1 |
Advancing Korean nationwide registry for hepatocellular carcinoma: a systematic sampling approach utilizing the Korea Central Cancer Registry database | Journal of Liver Cancer | Bo Hyun Kim E Hwa Yun Jeong-Hoon Lee Geun Hong Jun Yong Park | 2024/3/26 |
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment | Alimentary Pharmacology & Therapeutics | Hyeyeon Hong Minjoo Cho Chaeyeon Lim Won‐Mook Choi Danbi Lee | 2024/2 |
CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance | Alimentary Pharmacology & Therapeutics | Hye Won Lee Terry Cheuk‐Fung Yip Vincent Wai‐Sun Wong Young‐Suk Lim Henry Lik‐Yuen Chan | 2024/2/29 |
Outcomes of Liver Resection and Transarterial Chemoembolization in Patients with Multinodular BCLC-A Hepatocellular Carcinoma. | Journal of Liver Cancer | Jiwon Yang Won-Mook Choi Danbi Lee Ju Hyun Shim Kang Mo Kim | 2024/4/3 |
Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals | Gut and Liver | Hyeyeon Hong Won-Mook Choi Danbi Lee Ju Hyun Shim Kang Mo Kim | 2024/1/1 |
Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV immunotherapy (VTP-300) combined with low-dose nivolumab (LDN) in virally suppressed patients with CHB on nucleos (t) ide … | J. Hepatol. | T Evans L Bussey SL Teo A Tria A Brown | 2023 |
Liver Cirrhosis Increases the Risk of Herpes Zoster: A Nationwide Population-Based Cohort Study | Official journal of the American College of Gastroenterology| ACG | Dongsub Jeon Ye-Jee Kim Seonok Kim Won-Mook Choi Danbi Lee | 2023/9/1 |
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B | JHEP Reports | Young-Suk Lim Henry LY Chan Sang Hoon Ahn Wai Kay Seto Qin Ning | 2023/10/1 |
Tenofovir alafenamide for multiple drug-resistant chronic hepatitis B: a 3-year clinical trial | Clinical Gastroenterology and Hepatology | Jonggi Choi Young-Suk Lim Ji-Hoon Kim Kwan Soo Byun Byung Chul Yoo | 2023/11/1 |
New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block? | Clinical and Molecular Hepatology | Young-Suk Lim | 2023/1 |
Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study | Hepatology Communications | Man‐Fung Yuen Elina Berliba Wattana Sukeepaisarnjaroen Sang Hoon Ahn Tawesak Tanwandee | 2022/12 |
Co-Authors
